Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2005

View Archived Issues

Human Genome Sciences updates 2004 progress

Tipifarnib NDA submission complete to CMA Pilot-1 Program

Neurosearch receives payment for NS-2330 development

Abraxane set for February launch

ND-7001 enters phase I

TPI-287 set to enter phase I

Enrollment begins in phase I formulation study of DB-289

Quigley Pharma advances R&D programs

New funds to accelerate clinical development programs at ChemGenex

Merck's HIV/AIDS vaccine candidate enters collaborative phase II study

Phase II study of h-R3 in pediatric glioma progresses to phase III

Engineering of monoclonal antibody BT-062 successfully completed

Positive opinion for new Thyrogen indication in Europe

U.K. approves phase I/II trial of topical Melanotan

Genesis Bioventures and Corgenix Medical merger terminated

Protein Design Labs to acquire ESP Pharma

Antimalarial effects of the root extract fagaronine shown in vitro

KG-501: a small-molecule inhibitor of CREB:CBP activator:coactivator interaction

Acyclic retinoid inhibits FGF signaling in hepatoma cells

New Zealand researchers develop novel broad-spectrum fungicide

New combinations for the treatment of multiple sclerosis

K-11706 shows promise in orally treating ACD

Altana claims new combinations for respiratory disorders

Nociceptin analogues described in patent literature

Scientists at Cytokinetics report novel agents for proliferative diseases

New HIV integrase inhibitors prepared and tested at BMS

New compounds for the treatment of HCV infections

Biovitrum discloses 11beta-HSD1 inhibitors for diabetes, obesity, etc.

Bound follicle-stimulating hormone crystal structure determined

Imatinib study identifies potential new pathway for asthma treatment

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026